Evidence map›Paper›PMID 42867565›Full record

ArticleScience China. Life sciences2026

β2-adrenergic receptor agonist regulates macrophage polarization via HMGB1 in immune thrombocytopenia.

Qiuyu Guo, Yejun Wu, Gaochao Zhang, Qingyuan Qu, Zhuoyu An, Mengtong Zang, Lulu Wang, Menglin Li, Yuxiu Chen, Jianying Zhou and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Qiuyu Guo *Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Yejun Wu *Peking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Gaochao ZhangPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Qingyuan QuPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Zhuoyu AnPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Mengtong ZangPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Lulu WangPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Menglin LiPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Yuxiu ChenPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Jianying ZhouPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Mengyu XiaoPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Jingli HanPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Peng ZhaoPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Yuanyuan ZhangPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Haixia FuPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China.
Qiusha HuangPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China. huangfuqs@163.com.
Xiaohui ZhangPeking University People's Hospital, Peking University Institute of Hematology; National Clinical Research Center for Hematologic Disease; Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, 100044, China. zhangxh@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An imbalance in M1/M2 polarization is linked to the pathogenesis of immune thrombocytopenia (ITP). Terbutaline, a β2-adrenergic receptor agonist, can significantly increase the percentage of Tregs, attenuating thrombocytopenia in ITP. The effect of terbutaline on M1/M2 polarization in ITP remains uncertain. This study aimed to elucidate the connection between splenic sympathetic nerves and macrophage polarization and to assess the effect of terbutaline on macrophages in ITP. Peripheral blood-derived CD14

Indexed as

high-mobility group box 1 (HMGB1)immune thrombocytopeniamacrophagesβ2 adrenergic receptor (β2-AR)

Identifiers

PMID42867565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.